Daratumumab meets endpoint as first-line multiple myeloma therapyDanish Genmab A/S’ anti-CD38 antibody daratumumab has met the endpoint of progression-free survival in an interim analysis of Genmab’s pivotal Phase III study aimed at receiving FDA approval as first-line … more ➔
Macrophage Pharma backed by Merck VenturesMerck Ventures has joined the Series A investor syndicate of the British immuno-oncology specialist Macrophage Pharma Ltd. more ➔
Parkinson’s: factor protects from neuron decay Scientists at Swedish Karolinska Institute have identified a factor that supports growth of midbrain dopaminergic (mDA) neurons, the nerve cells that degenerate during of Parkinson’s disease. more ➔
Topas Therapeutics lands option deal with Eli LillyEvotec’s immunology spin-out Topas Therapeutics has inked a multi-year R&D collaboration with pharma major Eli Lilly. The initial focus of research, which will be financed by Eli Lilly, is on identification … more ➔
Medivir licenses HCV drug MIV-802 to Chinese AscletisMedivir AB has exclusively licenced Greater China development and commercialisation rights of its preclinical candidate drug MIV-802 to Chinese drug developer Ascletis Bioscience Co. Ltd. more ➔
Swedish reasearchers link up cancer survival to protein levelsUsing a national supercomputer, Swedish researchers have analysed how protein expression of the 315 known cancer genes translates into cancer overall survival. more ➔
Metsä Group started up its bioproduct millFinnish Metsä Group has started its mill for bio-based products. The €1.2bn investment’s production capacity is 1.3 million tonnes of softwood pulp a year. more ➔
Oxford Immunotec value drops after public offeringUK-headquartered immunodiagnostics specialist Oxford Immunotec Global plc’s share value slipped by $1.31 to $16.02 after the company raised US-$40.125m on Monday in an public offering of 2.5 million … more ➔
Mundipharma pays US$250 for CAP7.1 German CellAct GmbH has cashed in US$250m (€212m) from Mundipharma in a licence deal for CAP7.1, a Phase II drug to treat the rare biliary tract cancer. more ➔
Sepsis: Adrenomed receives approval for POC study in patients with early septic shockGermany is the first country that has granted full approval to Adrenomed to conduct a Phase II study with the monoclonal antibody adrecizumab in patients with early septic shock. Within the ADR-02 … more ➔
